You are viewing the site in preview mode
Skip to main content
|
Characteristics
|
N (%)
|
|---|
|
Total advanced incident cancer cases from January 1, 2010 to January 31, 2018 (N, %)a,b
| |
|
Advanced stage at diagnosis, N (%)c
|
12,237 (96.67%)
|
|
Diagnosed as early stage and progressed to advanced stage, N (%)
|
422 (3.33%)
|
|
Age (years)
|
|
Mean (SD)
|
61.94 (14)
|
|
Q1
|
53
|
|
Median
|
62
|
|
Q3
|
72
|
|
Region
|
|
Midwest
|
3436 (28.48%)
|
|
Northeast
|
2293 (19.01%)
|
|
South
|
2976 (24.67%)
|
|
West
|
3358 (27.84%)
|
|
Year of index date
|
|
2010-2011
|
4712 (37.22%)
|
|
2012-2014
|
4468 (35.30%)
|
|
2015-2018
|
3479 (27.48%)
|
|
Plan type
|
|
Commercial
|
9288 (73.37%)
|
|
Medicare Advantage
|
1511 (11.94%)
|
|
Medicare, Other
|
1860 (14.69%)
|
|
Duration of health plan membership prior to advanced stage index date (months)
|
|
Mean (SD)
|
48.16 (28.25)
|
|
Q1
|
23.24
|
|
Median
|
48.20
|
|
Q3
|
68.86
|
|
Duration of follow-up (months)
|
|
Mean (SD)
|
24.52 (23.28)
|
|
Q1
|
6.47
|
|
Median
|
17.25
|
|
Q3
|
35.19
|
|
Deyo-Charlson Comorbidity Index (DCI) during follow-up
|
|
Mean (SD)
|
6.34 (2.63)
|
|
Q1
|
5
|
|
Median
|
6
|
|
Q3
|
8
|
|
Number of drugs dispensed during follow-up
|
|
Mean (SD)
|
12.61 (9.76)
|
|
Q1
|
5
|
|
Median
|
11
|
|
Q3
|
18
|
- Abbreviations: N Number, SD Standard deviation, US United States, Q Quartile, ED Emergency department.
- aThe cohort includes patients who had at least one ICD-9-CM or ICD-10 diagnosis code for ovarian cancer, were continuously enrolled in a health plan contributing data to the HIRD for at least six months, and were confirmed to have advanced ovarian cancer based on staging information from either a cancer registry or the HIRE Oncology data or met the predictive model algorithm for advanced stage ovarian cancer.
- bIncident cases are individuals for whom at least six months of data were available in the HIRD prior to the first diagnosis of ovarian cancer in claims.
- cCases are defined as "advanced stage at diagnosis" if their advanced stage date (from cancer registry, HIRE Oncology, or predictive model) was within one month of their first cancer diagnosis in claims, otherwise they are defined as "Diagnosed as early stage and progressed to advanced stage".
